These include age, body mass index (BMI), prostate-specific antigen (PSA), prior biopsies, prostate volume, American Urological Association symptom score, Charlson Comorbidity Index, Total Illness Burden Index for Prostate Cancer score, race, the presence of diabetes mellitus, a history of urinary tract infections, family members in health care, hospitalization for illness in the last 12 months, presence of prostate cancer, a history of FQ use, and a history of non-FQ antibiotics use. This evidence concerns the gene KLK3 and diabetes mellitus.